Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Michigan Acitretin Prior …
    Ask Trek AI about this page
    Currentblue cross blue shield - michiganPolicy N/A

    Acitretin prior authorization and coverage summary

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists prior authorization (PA) and step therapy (ST) criteria for Acitretin and many other medications for Blue Cross Blue Shield of Michigan Medicare Plus Blue Group PPO and Prescription Blue Group PDP members; it affects prescribers and pharmacies seeking coverage for these drugs. The Acitretin entry specifies coverage duration and that no prerequisite Part D drug is required.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin prior authorization and coverage summary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with required documentation to obtain one-year coverage for Acitretin.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    One YearCoverage duration for Acitretin
    PA listedAcitretin PA status
    Not requiredPrerequisite Part D drug
    EXAMPLES

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Notable exclusions
    20+Products listed (partial)

    Coverage Criteria and Product Summaries

    Initial Therapy — Covered when the listed PA criteria are met

    Covered when the listed PA criteria are met

    Acitretin coverage requirements: Coverage for Acitretin requires meeting prior authorization criteria as listed; coverage duration is one year; no prerequisite Part D drug is required.

    Off-label uses, exclusion criteria, required medical information, age and prescriber restrictions are noted as N/A in this section.

    Per-product PA criteria summaries — selected entries

    Each product entry lists indication scope, exclusion, required documentation, coverage duration, and prerequisite therapy where specified.

    Augtyro: Indications: All Medically-accepted Indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: does not require a prerequisite Part D drug.

    chunk 18

    Auryxia: Indications: All Medically-accepted Indications; Coverage Duration: One Year; Prerequisite Therapy: does not require a prerequisite Part D drug.

    chunk 19

    Auvelity: Indications: All Medically-accepted Indications; Coverage for major depressive disorder requires a trial of bupropion and one other agent; Prerequisite Therapy: requires a prerequisite Part D drug.

    chunk 20

    Braftovi: Coverage for specified oncology indications requires combination use with other named agents (e.g., vemurafenib + cobimetinib for BRAF-mutant melanoma; cetuximab + fluorouracil-based chemotherapy for CRC; combination with binimetinib for NSCLC) and may require prior systemic therapy; Prerequisite Therapy: may require prior Part D drug for some indications.

    chunk 30

    Briviact: Coverage requires trial of levetiracetam and one other antiseizure medication before approval; Prerequisite Therapy: requires a prerequisite Part D drug.

    chunk 31

    Bronchitol: Requires documentation that the member has passed the Bronchitol tolerance test; Coverage Duration: 1 YEAR; Prerequisite Therapy: does not require a prerequisite Part D drug.

    chunk 32

    Brukinsa: Coverage for mantle cell lymphoma, marginal zone lymphoma, follicular lymphoma, CLL/SLL requires trials or combination with specified agents (e.g., Calquence, anti-CD20 regimens, obinutuzumab, Imbruvica); Prerequisite Therapy: requires prerequisite Part D drug(s).

    chunk 33

    Budesonide (ER): Indications: All Medically-accepted Indications with explicit exclusion: maintenance of remission in ulcerative colitis is not covered; Prerequisite Therapy: does not require a prerequisite Part D drug.

    chunk 34

    Bysanti: Coverage for schizophrenia in adults requires trials of lurasidone AND paliperidone; for other indications requires trial of at least two listed generic antipsychotics (aripiprazole, asenapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone); Coverage Duration: PLAN YEAR; Prerequisite Therapy: requires prerequisite Part D drug.

    chunk 36

    General PA entries (partial doc)

    Products and general PA notes (selected highlights from this partial listing)

    PA general requirements: Prior authorization entries commonly indicate 'All Medically-accepted Indications'; many products require prerequisite therapy or prior trials and coverage durations are typically one year or plan-year as specified per product.

    See individual product entries for details (e.g., prerequisite therapy presence varies).

    Tadalafil explicit exclusion

    Tadalafil exclusion: Coverage is not provided for tadalafil in situations where patients are receiving nitrate therapy.

    Explicit exclusion — concurrent nitrate therapy prohibited.

    Cabometyx criteria highlights

    Cabometyx specific requirements: First-line treatment of advanced renal cell carcinoma requires combination use with nivolumab; hepatocellular carcinoma treatment requires a trial of sorafenib; locally advanced or metastatic differentiated thyroid cancer that is radioactive iodine–refractory or ineligible requires a trial of VEGFR-targeted therapy.

    Prerequisite therapy required for these indications.

    Clomiphene (Clomid) — Initial/General coverage criteria

    Clomiphene (Clomid) coverage

    Clomiphene PA: Indications: All Medically-accepted Indications; Coverage Duration: 1 YEAR; Prerequisite Therapy: does not require a prerequisite Part D drug.

    Off-label uses: N/A.

    Cometriq — Initial/General coverage criteria

    Cometriq coverage

    Cometriq PA: Indications: All Medically-accepted Indications; Coverage Duration: One Year; Prerequisite Therapy: does not require a prerequisite Part D drug.

    Off-label uses: N/A.

    Copaxone — Initial/General coverage criteria

    Copaxone (Glatiramer) coverage

    Copaxone PA: Indications: All Medically-accepted Indications; Coverage Duration: 1 Year; Prerequisite Therapy: does not require a prerequisite Part D drug.

    Cosentyx — Indication-specific criteria

    Cosentyx coverage

    Cosentyx PA general: Indications: All Medically-accepted Indications; Coverage Duration: 1 YEAR; Reauthorization requires documentation of positive clinical response; Exclusion: cannot be used in combination with another biologic or targeted DMARD for the same condition.
    Cosentyx indication-specific requirements: Psoriatic arthritis: diagnosis of active PsA required; Plaque psoriasis: diagnosis of moderate to severe chronic plaque psoriasis required; Ankylosing spondylitis: diagnosis of AS and trial of one NSAID required; Non-radiographic axial spondyloarthritis: diagnosis with objective signs of inflammation and trial of one NSAID required; Enthesitis-related arthritis: diagnosis of active ERA and trial of one NSAID required; Hidradenitis suppurativa: diagnosis of moderate to severe HS required.

    Prerequisite therapy required for specified indications.

    Cobenfy — Schizophrenia prerequisite

    Cobenfy coverage

    Cobenfy PA: Indications: All Medically-accepted Indications; Coverage for schizophrenia requires trial of at least two second-generation antipsychotics; Prerequisite Therapy: requires a prerequisite Part D drug.

    Copiktra — Relapsed/refractory CLL coverage criteria

    Copiktra coverage

    Copiktra PA: Indications: All Medically-accepted Indications; Coverage for relapsed or refractory chronic lymphocytic leukemia (CLL) requires at least two prior therapies; Prerequisite Therapy: requires prior Part D drug therapy.

    Dalfampridine — MS-specific coverage and exclusions

    Dalfampridine coverage

    Dalfampridine PA: Indications: All Medically-accepted Indications; Coverage for multiple sclerosis requires documentation of a baseline Timed 25-Foot Walk (T25FW) test prior to initiation; Exclusion: excluded for use if the patient is wheelchair-bound or becomes wheelchair-bound; Prerequisite Therapy: does not require a prerequisite Part D drug.

    Baseline T25FW required prior to initiation.

    Product-specific PA summary (chunk 90)

    General PA and coverage attributes for the product(s) listed in chunk 90

    Core PA requirements (example): PA criteria apply; patient must weigh at least 40 kilograms; patient must be at least 12 years of age; exclusion: cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; coverage duration 1 year; prerequisite Part D drug required as indicated.

    Reauthorization requires documentation of positive clinical response for certain indications.

    Enbrel coverage criteria

    Enbrel-specific coverage criteria excerpts

    Enbrel RA and related indications: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA AND trial of one disease-modifying antirheumatic drug (DMARD) such as methotrexate, leflunomide, or sulfasalazine; other indication-specific trial requirements apply for JIA, PsA, plaque psoriasis, and AS (trial of an NSAID for AS). Reauthorization requires documentation of positive clinical response to therapy.

    Topiramate coverage criteria

    Topiramate (Eprontia) indication-specific requirements

    Topiramate for migraine prevention or inability to swallow: Coverage for preventive treatment of migraine requires either: (1) trial of at least 2 generic alternatives for migraine prevention OR (2) patient is unable to swallow tablets/capsules.

    Epidiolex coverage criteria

    Epidiolex indication-specific requirements

    Epidiolex seizure syndrome trials: Coverage for Lennox-Gastaut syndrome requires trial of 2 generic alternatives for seizure treatment; Dravet syndrome requires trial of 2 of: valproic acid, clobazam, or topiramate; seizures associated with tuberous sclerosis complex require trial of 2 generic alternatives.

    Prerequisite Part D drug required.

    Product-specific PA summaries (group)

    Coverage is generally provided for medically-accepted indications where specified; some products have additional indication-specific criteria or exclusions.

    GLP-1 agonists coverage: Covered for medically-accepted indications for type 2 diabetes mellitus with required documentation (A1c >= 6.5% OR FPG >= 126 mg/dL OR 2-hour OGTT >= 200 mg/dL); excluded if used solely for weight loss; Coverage Duration: 1 year.A1c >= 6.5% OR FPG >= 126 mg/dL OR 2-hour OGTT >= 200 mg/dL

    chunk 148

    Humira coverage (example): Covered for specified immune-mediated indications with indication-specific diagnostic severity and prerequisite therapy trials where listed; reauthorization requires demonstration of positive clinical response; Exclusion: cannot be used in combination with another biologic or targeted DMARD for the same condition.

    chunks 161-163

    Growth hormone coverage: Genotropin products covered for medically-accepted indications; pediatric coverage duration = 1 year; adult coverage may be lifetime.

    Indication-specific initial coverage

    Coverage is provided for specific medically-accepted indications when listed prerequisites and disease severity requirements are met. Reauthorization requires clinical improvement.

    Example — Rheumatoid arthritis initial coverage: Coverage for rheumatoid arthritis for one year requires: diagnosis of moderately to severely active RA AND trial of one DMARD (e.g., methotrexate, leflunomide, or sulfasalazine).1 trial of DMARD

    chunk 162

    Other indication prerequisites

    Ankylosing spondylitis prerequisite: Coverage requires a diagnosis of active ankylosing spondylitis and a trial of one NSAID (e.g., diclofenac, ibuprofen, meloxicam, naproxen).1 trial of NSAID

    chunk 162

    General product PA rule

    Products listed are subject to PA criteria with the indicated summary elements

    General product PA rule: Each listed product has PA Criteria stating indications (often 'All Medically-accepted Indications'), Off-Label Uses (often N/A), Exclusion Criteria (where noted), Required Medical Information, Age/Prescriber Restrictions, Coverage Duration (often one year), Other product-specific criteria, and Prerequisite Therapy (required or not as listed).

    Summary from product lines (chunk 181).

    Inlyta coverage condition

    Inlyta specific coverage condition

    Inlyta for first-line advanced RCC: Coverage for first-line treatment of advanced renal cell carcinoma requires combination use with avelumab or pembrolizumab; prerequisite: trial of one prior systemic therapy as indicated.

    chunk 186

    Inqovi prerequisite

    Inqovi specific prerequisite therapy

    Inqovi prerequisite: Coverage requires trial with azacitidine prior to Inqovi use.

    chunk 189

    Isotretinoin prerequisite

    Isotretinoin coverage prerequisite

    Isotretinoin prior therapy: Coverage requires trial of either an oral antibiotic OR a benzoyl peroxide–containing topical prior to approval.

    chunk 195

    Prior authorization criteria summaries (partial)

    Products in this section are subject to prior authorization; entries summarize key coverage requirements where provided.

    Ivermectin TABS 3MG listed with PA Criteria referenced; see full policy for detailed criteria.

    chunk 199

    Deferasirox (Jadenu): Deferasirox tablets: Indications = All Medically-accepted Indications; Coverage Duration = One Year; Prerequisite Therapy: does not require a prerequisite Part D drug.1 year

    chunk 202

    Jakafi: Coverage for polycythemia vera requires inadequate response or intolerance to hydroxyurea; prerequisite trial(s) of systemic therapy noted.

    chunk 205

    Jaypirca: Mantle cell lymphoma coverage requires two prior lines of systemic therapy including a BTK inhibitor; Prerequisite Therapy: requires prior Part D drug use.

    chunk 207

    Kerendia (example) — selected notes

    Selected product-specific coverage notes (examples shown below).

    Kerendia — CKD indication: Coverage is provided for chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM); Coverage Duration: 1 year; Prerequisite Therapy: may require prior SGLT2 inhibitor trial for HF indication unless contraindicated.

    chunk 216

    Kevzara criteria highlights

    Kevzara coverage requirements for listed indications.

    Kevzara general: Cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; Coverage Duration: 1 year; Prerequisite Therapy: requires trials of specified agents for some indications; Reauthorization requires documentation of positive clinical response.

    chunk 220

    Kevzara — RA initial therapy: Coverage for rheumatoid arthritis requires diagnosis of moderately to severely active RA and trial of two of the following: Enbrel, adalimumab (brand variants), Rinvoq, Xeljanz/XR, Orencia.trial of two agents

    chunk 220

    Kisqali coverage criteria

    Kisqali coverage requirements for breast cancer indications.

    Kisqali — advanced/metastatic HR+/HER2-: Coverage for HR-positive, HER2-negative advanced or metastatic breast cancer requires combination use with an aromatase inhibitor as initial endocrine-based therapy or fulvestrant as initial endocrine-based therapy or following progression on endocrine therapy; Coverage Duration: 1 year; Prerequisite Therapy: requires prior Part D drug(s) as indicated.combination endocrine therapy required

    chunk 226

    Kisqali — early stage high risk: Coverage for stage II/III early breast cancer at high risk of recurrence requires combination use with an aromatase inhibitor.combination therapy required

    chunk 226

    Krazati criteria

    Krazati coverage note.

    Krazati: Coverage for KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer; prerequisite: prior systemic therapy required for certain indications.prior systemic therapy

    chunk 233

    Product PA summaries (partial list)

    Product-specific coverage and prerequisite summaries (partial list from document)

    Liraglutide: Covered for medically-accepted indications except excluded when used for treatment of weight loss only. Requires submission of medical records confirming diagnosis of T2DM or lab evidence: A1c ≥6.5% OR FPG ≥126 mg/dL OR 2-hour OGTT ≥200 mg/dL. Coverage Duration: 1 year; Prerequisite Therapy: does not require a prerequisite Part D drug.A1c >= 6.5% OR FPG >= 126 mg/dL OR 2-hour OGTT >= 200 mg/dL

    chunk 252

    Livtencity: Covered for medically-accepted indications. Coverage for post-transplant CMV infection/disease requires trial of valganciclovir, cidofovir, or foscarnet (prerequisite antiviral therapy).

    chunk 253

    Lonsurf: Covered for medically-accepted indications; coverage for metastatic colorectal cancer requires combination use with bevacizumab and prior trials of fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and an anti-VEGF; Coverage Duration: 1 year.

    chunk 254

    None listed. Exclusion Criteria: N/A.

    Budesonide extended-release is excluded for maintenance of remission in ulcerative colitis; coverage will not be provided for that use.

    Tadalafil is explicitly excluded when patients are receiving nitrate therapy; claims for tadalafil in the setting of concomitant nitrates will not be covered.

    Dalfampridine ER is excluded for use if the patient is wheelchair-bound or becomes wheelchair-bound. For multiple sclerosis, a baseline Timed 25-Foot Walk (T25FW) must be documented prior to initiation.

    Use of a biologic or targeted DMARD in combination with another biologic or targeted DMARD indicated for the same condition is excluded; several product lines state this combination is not permitted and may trigger denial.

    GLP‑1 receptor agonists are excluded when used solely for weight loss. Separately, Humira (adalimumab products) and similar biologics are excluded from combination use with another biologic/targeted DMARD for the same indication.

    Some product entries explicitly list Off‑Label Uses: N/A and Exclusion Criteria: N/A, indicating no off‑label coverage or no exclusions were noted for those specific lines in the excerpts provided.

    Actions, Documentation, and Denial Risks for Providers

    Prior Authorization

    Acitretin — prior authorization required (1 year)

    Acitretin is subject to prior authorization. Coverage is provided when the PA criteria are met and, per the Acitretin entry, authorization is granted for one year; no prerequisite Part D drug is required.

    Prior Authorization

    Augtyro — PA: 1 year; no prerequisite Part D drug

    Augtyro requires prior authorization for all medically-accepted indications; coverage duration is 1 year and the entry indicates no prerequisite Part D drug is required.

    Prior Authorization

    Auryxia — PA: one year; no prerequisite Part D drug

    Auryxia (ferric citrate) requires prior authorization for all medically‑accepted indications; coverage duration is one year and no prerequisite Part D drug is required.

    Codes, Tests, and Measured Criteria

    Timed 25-Foot Walk (T25FW) — baseline required prior to initiation
    RequirementBaseline Timed 25‑Foot Walk (T25FW) test must be documented prior to initiation of dalfampridine for multiple sclerosis
    ScopeApplies to coverage for treatment of MS-related walking impairment (Dalfampridine ER)
    Exclusion linkDalfampridine is excluded if patient is wheelchair‑bound or becomes wheelchair‑bound
    A1c threshold for diabetes documentation
    A1c threshold>= 6.5%
    Use context

    Initial Authorization Requirements

    Reauthorization and Continuation Requirements

    Step Therapy (Prerequisite Part D Drug) Table

    StepRequirement
    0Criteria DOES NOT require use of a prerequisite Part D drug for Acitretin. Coverage Duration: One Year; PA required.
    StepRequirement
    1Several products require trials of specific prior agents or combination use with specified drugs before coverage (examples: Braftovi requires combination use with vemurafenib + cobimetinib or binimetinib; Brukinsa requires trials of Calquence or anti‑CD20 regimens for certain lymphoma indications; Bysanti requires trials of lurasidone and paliperidone for schizophrenia or two listed generic antipsychotics for other indications; Cabometyx requires sorafenib trial for HCC and combination with nivolumab for first‑line advanced RCC).
    StepRequirement
    1Prior trial of specified generic antipsychotics: e.g., Bysanti requires trial of lurasidone and paliperidone for schizophrenia; for other antipsychotic indications a trial of at least two of the listed generics (aripiprazole, asenapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). Fanapt and Cobenfy also require trials of two generic atypical antipsychotics for schizophrenia.
    StepRequirement
    1Trial of at least one generic topical is required prior to coverage (calcipotriene entries specify a required trial of at least one generic topical).
    StepRequirement
    1Trial of specified prior therapy: examples include Cabometyx (trial of sorafenib for HCC; prior VEGFR‑targeted therapy for DTC) and Calquence (requirement that patient has received at least one prior therapy for mantle cell lymphoma); Brukinsa similarly lists prior therapy requirements for hematologic cancers.
    StepRequirement
    1Prior therapy required (general): many oncology and specialty agents require prior systemic therapies or specific prior agents (e.g., Braftovi, Copiktra require prior therapies per indication; Diacomit requires trial of 2 generic anticonvulsants with clobazam).
    StepRequirement
    1Requires trials of specified prior therapies for certain products: e.g., Cobenfy requires trial of at least two second‑generation antipsychotics for schizophrenia; Copiktra requires at least two prior therapies; Cosentyx lists prerequisite trials (NSAID) for some indications.
    StepRequirement
    1Trial of 2 generic anticonvulsants and combination with clobazam specified: Diacomit coverage requires trial of two generic anticonvulsants and combination use with clobazam.
    StepRequirement
    1Trial of two triptans on formulary required prior to coverage: Dihydroergotamine mesylate solution requires trial of one oral triptan and one non‑oral triptan.
    StepRequirement
    1Dupixent indication‑specific prior therapy trials required: for AD a trial and failure of high‑potency topical corticosteroid or listed systemic immunosuppressants; for eosinophilic asthma and corticosteroid‑dependent asthma specified systemic corticosteroid or high‑dose inhaled corticosteroid plus additional controller medication trials; age/weight thresholds and eosinophil counts apply depending on indication.
    StepRequirement
    1Trial of generics or examples of inability to swallow tablets/capsules: Topiramate (solution) for migraine prevention requires trial of at least two generic alternatives OR documented inability to swallow tablets/capsules.
    StepRequirement
    1Fanapt requires trial of two generic formulary atypical antipsychotics for schizophrenia (examples listed include quetiapine, risperidone, ziprasidone).
    StepRequirement
    1Fasenra eosinophilic asthma prerequisites: requires diagnosis with eosinophil count ≥150 cells/µL at initiation and failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus an additional asthma controller medication; reauthorization requires documentation of clinical response.
    StepRequirement
    1Prior trials required examples: Fotivda (advanced RCC) requires trial of two or more prior systemic agents; Fruzaqla (mCRC) requires prior fluoropyrimidine‑, oxaliplatin‑, irinotecan‑based chemotherapy and anti‑VEGF therapy; Fycompa requires trial of two generic alternatives prior to approval.
    StepRequirement
    1Step 1 (examples): some products list Step 1 prerequisite trials or conventional therapies (e.g., Gilotrif, Humira) — see individual product entries for specific Step‑1 requirements.
    StepRequirement
    1Prior trial(s) of specified therapies required as listed per product: examples include requirement of DMARD trial for RA, NSAID trial for ankylosing spondylitis, and trials of prior kinase inhibitors for certain CML indications.
    StepRequirement
    1Isotretinoin requires trial of antibiotic or benzoyl peroxide topical: coverage requires trial of either an oral antibiotic OR a benzoyl peroxide‑containing topical prior to approval.
    StepRequirement
    1Inqovi requires prior trial with azacitidine: coverage requires a trial of azacitidine before Inqovi is approved.
    StepRequirement
    1Jaypirca mantle cell lymphoma requires two lines of systemic therapy including a BTK inhibitor: coverage for MCL requires prior trial of two systemic therapy lines that include a BTK inhibitor.
    StepRequirement
    1Jylamvo requires prior trial of methotrexate tablet or documented inability: coverage requires trial of methotrexate tablet or documentation that the patient cannot use methotrexate tablets.
    StepRequirement
    1Kerendia for heart failure with LVEF ≥40% requires SGLT2 trial: coverage requires a trial of an SGLT2 inhibitor (e.g., empagliflozin, dapagliflozin) unless contraindicated or intolerant.
    StepRequirement
    1Kevzara/Kisqali/Krazati examples: Kevzara requires trials of specified agents (e.g., trial of two listed therapies for RA); Kisqali requires combination endocrine therapy with an aromatase inhibitor or fulvestrant; Krazati requires prior systemic therapy for KRAS G12C‑mutated disease — see product lines for specifics.
    StepRequirement
    1Combination use with amivantamab required: Lazcluze entry specifies coverage requires combination use with amivantamab for certain locally advanced treatments.
    StepRequirement
    1RCC first‑line requires combination with pembrolizumab or everolimus examples: Lenvima requires combination with pembrolizumab for first‑line RCC; other RCC indications require combination with everolimus after prior anti‑angiogenic therapy.
    StepRequirement
    1Libtayo basal cell carcinoma requires prior hedgehog pathway inhibitor treatment: coverage for BCC requires prior hedgehog pathway inhibitor therapy before Libtayo is approved.
    StepRequirement
    1Prerequisite antiviral trial required (general): some products (e.g., Livtencity) require a prior trial of specified antivirals before coverage is granted.
    StepRequirement
    1Livtencity requires trial of valganciclovir, cidofovir, or foscarnet prior to coverage: coverage for post‑transplant CMV infection/disease requires documentation of a trial of one of these antivirals.
    StepRequirement
    1Lonsurf requires prior trials of standard chemotherapies for mCRC: coverage for metastatic colorectal cancer requires prior fluoropyrimidine‑, oxaliplatin‑, irinotecan‑based chemotherapy and anti‑VEGF therapy and combination use with bevacizumab.
    StepRequirement
    1Lumakras requires trial of at least one prior systemic therapy: coverage for KRAS G12C‑mutated locally advanced or metastatic NSCLC requires prior systemic therapy (at least one agent).

    Background and Policy Scope

    Blue Cross Blue Shield of Michigan uses prior authorization and step therapy to manage formulary drugs; PA entries list indications, exclusions, required medical information, coverage duration, and prerequisite therapy where applicable. These utilization management tools are applied to ensure clinically appropriate and cost‑effective drug therapy for members.

    Definitions and Key Terms

    PA — Prior authorization (PA)
    DefinitionPrior authorization (PA) — clinical and/or administrative criteria that must be met before coverage is provided
    Typical elementsPA entries include indications, exclusion criteria, required medical information, age/prescriber restrictions, coverage duration, and prerequisite therapy
    Coverage durationMany PA entries specify a coverage duration of 1 year
    ST — Step therapy (ST)
    DefinitionStep therapy (ST) — requirement to try one or more formulary drugs prior to coverage of the requested drug
    ApplicationSome formulary drugs require ST; Acitretin entry explicitly does not require a prerequisite Part D drug

    Policy Revision History

    2026-07-01effective_dateLatest

    Policy effective date set to 2026-07-01 for the Medicare Plus Blue Group PPO and Prescription Blue Group PDP formulary prior authorization/step therapy program.

    2026-07-01last_review

    Policy last revised and reviewed on 2026-07-01 (document indicates 'Last revised 2026-07-01').

    2026-07-01publication_note
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyAcitretin prior authorization and coverage summary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with required documentation to obtain one-year coverage for Acitretin.
    SourceLink
    On This Page
    Coverage Criteria and Product SummariesActions, Documentation, and Denial Risks for ProvidersCodes, Tests, and Measured CriteriaInitial Authorization RequirementsReauthorization and Continuation RequirementsStep Therapy (Prerequisite Part D Drug) TableBackground and Policy ScopeDefinitions and Key TermsPolicy Revision History

    chunk 153

    Joenja: Coverage for APDS requires documented PI3Kδ mutation (variant in PIK3CD or PIK3R1) and associated symptoms; exclusion: cannot be used in combination with an immunosuppressive medication; Coverage Duration: 1 YEAR.

    chunk 209

    Jylamvo: Coverage requires trial of methotrexate tablet or documented difficulty with its use; Prerequisite Therapy: requires Part D drug trial.

    chunk 210

    Tolvaptan (Jynarque): Tolvaptan tablets: Indications = All Medically-accepted Indications; Coverage Duration = 1 YEAR; Prerequisite Therapy: does not require a prerequisite Part D drug.1 year

    chunk 212

    Kalydeco: Indications = All Medically-accepted Indications; Coverage Duration = 1 Year; Prerequisite Therapy: does not require a prerequisite Part D drug.1 year

    chunk 214

    Kerendia: Coverage provided for CKD associated with T2DM; coverage for heart failure with LVEF ≥40% requires trial of an SGLT2 inhibitor (e.g., empagliflozin or dapagliflozin) unless contraindicated; Coverage Duration: 1 YEAR; Prerequisite Therapy: requires prior Part D drug trial when indicated.1 year

    chunk 216

    Lorbrena: Covered for medically-accepted indications; Coverage Duration: One Year; Prerequisite Therapy: does not require a prerequisite Part D drug per entry.1 year

    chunk 256

    Lynparza: Covered for medically-accepted indications with multiple indication-specific prior therapy requirements (e.g., platinum-based chemotherapy for ovarian cancer); Coverage Duration: One Year.1 year

    chunk 261

    Lytgobi: Covered for medically-accepted indications; Coverage Duration: 1 Year; Prerequisite Therapy: does not require a prerequisite Part D drug.1 year

    chunk 264

    Mekinist: Covered for medically-accepted indications; Coverage Duration: 1 Year. Multiple combination and prior-therapy requirements noted for BRAF-mutated indications (requires trials/combination with specified BRAF/MEK inhibitors).1 year

    chunk 269

    Prior Authorization

    Auvelity — PA: MDD requires trial of bupropion + one other agent

    Auvelity requires prior authorization for all medically‑accepted indications. For major depressive disorder, the entry requires a trial of bupropion and one other agent (prerequisite Part D drug trial required).

    Prior Authorization

    Braftovi — PA: combination therapy and prior therapy requirements

    Braftovi is subject to prior authorization; coverage for listed oncology indications requires specified combination use (e.g., vemurafenib + cobimetinib for BRAF-mutant melanoma, cetuximab + fluorouracil-based chemotherapy for CRC) and some indications require prior systemic therapy (prerequisite Part D drug required).

    Prior Authorization

    Brukinsa — PA: prerequisite trials or combination therapy

    Brukinsa requires prior authorization; certain hematologic indications require trials of or combination with specified agents (e.g., trial of Calquence for MCL; anti‑CD20 regimens or obinutuzumab for other lymphomas).

    Prior Authorization

    Bysanti — PA: antipsychotic prerequisite trials required

    Bysanti is subject to prior authorization. Coverage for schizophrenia in adults requires trials of lurasidone and paliperidone; for other antipsychotic indications coverage requires trials of at least two listed generic antipsychotics. Coverage duration is listed as plan year.

    Prior Authorization

    PA required — general note

    Prior authorization is required for many products listed in this document; individual product entries specify whether prerequisite Part D drug trials are required and most PA authorizations are for one year (or plan year) where noted.

    Prior Authorization

    Cabometyx — PA: prior trials / combination requirements

    Cabometyx requires prior authorization; first‑line advanced renal cell carcinoma coverage requires combination use with nivolumab, hepatocellular carcinoma coverage requires a trial of sorafenib, and certain differentiated thyroid cancer indications require prior VEGFR‑targeted therapy (prerequisite Part D drug required).

    Prior Authorization

    Prior Authorization required — 1 year (common)

    Several products on the formulary require prior authorization and list a coverage duration of one year; providers must meet the PA criteria referenced for each product to obtain coverage.

    Prior Authorization

    Cystaran — PA: all indications; 1 year

    Cystaran requires prior authorization for all medically‑accepted indications; coverage duration is one year per the product entry.

    Documentation Required

    Dalfampridine — PA: baseline T25FW required; wheelchair exclusion

    Dalfampridine ER requires prior authorization. For multiple sclerosis the PA requires documentation of a baseline Timed 25‑Foot Walk (T25FW) prior to initiation and the product is excluded if the patient is wheelchair‑bound or becomes wheelchair‑bound.

    • Document baseline T25FW prior to initiation
    • Do not initiate or continue if patient is wheelchair‑bound
    Prior Authorization

    Danyelza — PA: requires prior response/stable disease to prior therapy

    Danyelza requires prior authorization for relapsed or refractory high‑risk neuroblastoma; coverage is contingent on response or stable disease to prior therapy (prerequisite therapy noted).

    Prior Authorization

    Daurismo — PA: combination therapy required for newly diagnosed AML

    Daurismo requires prior authorization; coverage for newly diagnosed acute myeloid leukemia explicitly requires combination therapy per the product entry.

    Prior Authorization

    Deferasirox — PA: all indications; 1 year

    Deferasirox (tablets/TBSO) requires prior authorization for all medically‑accepted indications; the product entry lists a one‑year coverage duration and does not note prerequisite Part D drug trials.

    Step Therapy

    Diacomit — PA: trial of 2 generics + clobazam combination required

    Diacomit requires prior authorization; coverage requires trial of two generic anticonvulsants and use in combination with clobazam for the listed indication.

    • Trial of 2 generic anticonvulsants required
    • Combination use with clobazam required
    Step Therapy

    Dihydroergotamine — PA: trial of oral + non‑oral triptan required

    Dihydroergotamine mesylate solution requires prior authorization; coverage requires trials of two triptans on the formulary: one oral triptan and one non‑oral triptan prior to approval.

    • Trial of one oral triptan and one non‑oral triptan required
    Prior Authorization

    Doptelet — PA: prior therapy required for chronic ITP

    Doptelet requires prior authorization for chronic immune thrombocytopenia and the entry specifies a trial of a previous therapy is required before coverage.

    Prior Authorization

    Drizalma — PA: all indications; 1 year

    Drizalma Sprinkle requires prior authorization for all medically‑accepted indications; coverage duration is one year.

    Prior Authorization

    Dulera — PA: diagnosis + prior therapy trial required

    Dulera requires prior authorization for asthma coverage; the entry requires a diagnosis of asthma and trial of one of the listed agents prior to approval (prerequisite therapy required).

    Prior Authorization

    Dupixent — PA: indication‑specific trials, exclusions, reauth requirements

    Dupixent requires prior authorization across multiple indications. PA criteria include indication‑specific prior therapy trials, diagnostic thresholds (e.g., eosinophil counts), age/weight minimums, an exclusion against combination use with another biologic/targeted DMARD for the same condition, and a one‑year coverage duration.

    • Cannot be used with another biologic/targeted DMARD for the same condition
    • Reauthorization requires documentation of positive clinical response
    Prior Authorization

    Ebglyss — PA: age/weight limits, prior trials, combination exclusion, 1 year

    Ebglyss requires prior authorization for patients ≥12 years old and who weigh at least 40 kg; coverage duration is one year. The entry prohibits combination use with another biologic/targeted DMARD for the same condition and requires prior therapy trials for atopic dermatitis; reauthorization requires documentation of positive clinical response.

    • Patient must weigh ≥40 kg
    • Age ≥12 years for indicated approvals
    • Cannot be used with another biologic/targeted DMARD for same condition
    • Reauthorization requires documentation of positive clinical response
    Prior Authorization

    PA, coverage duration, age limit — general

    PA criteria apply to the products in this section; where stated, coverage duration is one year and age limits (e.g., ≥12 years) are enforced per product entries.

    Prior Authorization

    Emgality — PA: 1 year

    Emgality requires prior authorization; the product entry lists a one‑year coverage duration.

    Prior Authorization

    Ensacove — PA: 1 year

    Ensacove requires prior authorization with a one‑year coverage duration per the product entry.

    Prior Authorization

    Erleada — PA: all indications; 1 year

    Erleada requires prior authorization for all medically‑accepted indications; coverage duration is one year per the product entry.

    Prior Authorization

    Esbriet — PA: all indications; 1 year

    Esbriet (pirfenidone) requires prior authorization; coverage duration is one year and indications are all medically‑accepted indications per the entry.

    Documentation Required

    Fasenra — PA: eosinophil/EGPA criteria; reauth requires clinical response

    Fasenra requires prior authorization with indication‑specific criteria (e.g., eosinophil thresholds for eosinophilic asthma, EGPA criteria). Reauthorization requires documentation of positive clinical response.

    • Eosinophil count thresholds and EGPA diagnostic criteria required
    • Reauthorization requires documentation of clinical response
    Prior Authorization

    Firazyr (Icatibant) — PA: all indications; no prerequisite Part D drug

    Firazyr (icatibant acetate) requires prior authorization for all medically‑accepted indications; no prerequisite Part D drug is required per the product entry.

    Prior Authorization

    Firdapse — PA: all indications; 1 year; no prerequisite Part D drug

    Firdapse requires prior authorization for all medically‑accepted indications; authorization is granted for one year and no prerequisite Part D drug is required.

    Documentation Required

    Forteo — PA: BMD T‑score ≤ −2.5 and prerequisite therapy documentation

    Forteo (teriparatide) requires prior authorization. Documentation of bone mineral density with a T‑score ≤ −2.5 is required and two‑year coverage requires trials of the specified agents (or inability to be treated with them).

    • BMD documentation: T‑score ≤ −2.5 required
    • Two‑year coverage requires trials of the named agents (or documented inability to use them)
    Prior Authorization

    Fotivda — PA: prior systemic therapy required for advanced RCC

    Fotivda requires prior authorization; coverage for advanced renal cell carcinoma requires prior systemic therapy trials (trial of two or more prior systemic agents).

    Prior Authorization

    Fruzaqla — PA: prior chemo + anti‑VEGF required for mCRC

    Fruzaqla requires prior authorization for metastatic colorectal cancer; coverage requires prior fluoropyrimidine‑, oxaliplatin‑, irinotecan‑based chemotherapy and anti‑VEGF therapy per the product entry.

    Prior Authorization

    Fulphila — PA: 1 year; no prerequisite Part D drug

    Fulphila requires prior authorization and is authorized for one year; no prerequisite Part D drug is required per the product entry.

    Documentation Required

    Gattex — PA: documentation of parenteral support ≥12 months required

    Gattex requires prior authorization and documentation that the patient has been dependent on parenteral support for 12 months or greater; authorization is for one year.

    • Document dependence on parenteral support ≥12 months
    Prior Authorization

    Gavreto — PA: RET fusion‑positive thyroid cancer; prior therapy considerations

    Gavreto requires prior authorization for RET fusion–positive thyroid cancer and the entry notes appropriate prior therapy (e.g., radioactive iodine when appropriate) per the PA details.

    Prior Authorization

    Fingolimod (Gilenya) — PA: all indications; no prerequisite Part D drug

    Gilenya (fingolimod) requires prior authorization for all medically‑accepted indications; no prerequisite Part D drug is required per the product entry.

    Prior Authorization

    GLP‑1 agonists — PA: T2DM documentation required; weight‑loss only excluded; 1 year

    GLP‑1 agonists (including Mounjaro, Ozempic, Rybelsus, Trulicity) require prior authorization; they are excluded if used solely for weight loss and, for ongoing T2DM treatment, require submission of medical records or labs demonstrating T2DM (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hour OGTT ≥200 mg/dL). Coverage duration is one year.

    • Do not cover if used for weight loss only
    • For T2DM, submit chart notes or labs: A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL
    • Coverage duration: 1 year
    Prior Authorization

    Growth hormone — PA: pediatric 1 year; adult may be lifetime

    Growth hormone products (Genotropin and Genotropin Miniquick) require prior authorization; pediatric coverage is authorized for one year and adult coverage may be lifetime as indicated.

    Prior Authorization

    Humira — PA: indication‑specific prerequisites; reauth requires clinical response

    Humira (adalimumab products) requires prior authorization with indication‑specific diagnostic and prerequisite therapy requirements; reauthorization requires documentation of a positive clinical response to therapy.

    • Reauthorization requires documentation of positive clinical response
    • Cannot be used in combination with another biologic/targeted DMARD for same condition
    Documentation Required

    Product-specific prior authorization — provide indicated documentation

    Many listed products are subject to product‑specific prior authorization. Providers must supply the required indication, required medical information, and any prerequisite trial documentation noted in the product PA criteria.

    Prior Authorization

    Ivermectin — PA required; risk of denial if criteria not met

    Ivermectin TABS 3 mg requires prior authorization per the PA criteria reference; coverage may be denied if PA criteria are not met.

    Denial Risk

    Deferasirox — PA: 1 year; denial risk if PA criteria not met

    Deferasirox tablets require prior authorization; coverage duration is limited to one year and coverage may be denied if PA criteria are not satisfied.

    Note
    Documentation Required

    Joenja — PA: genetic + clinical documentation required; 1 year

    Joenja requires prior authorization for APDS with specific genetic and clinical documentation: a diagnosis of APDS with associated PI3Kδ mutation, documented variant in PIK3CD or PIK3R1, and documented APDS‑related symptoms; coverage duration is one year and the product cannot be used in combination with an immunosuppressive medication for APDS.

    • Document PI3Kδ mutation and variant in PIK3CD or PIK3R1
    • Document associated APDS symptoms (e.g., lymphoproliferation, recurrent oto‑sino‑pulmonary infections, organ dysfunction)
    • Cannot be used with immunosuppressive medication for APDS
    Step Therapy

    Kerendia — PA: SGLT2 trial required for HF with LVEF ≥40% (unless contraindicated)

    Kerendia requires prior authorization; coverage for CKD associated with T2DM is provided, and coverage for heart failure with LVEF ≥40% requires a trial of an SGLT2 inhibitor (e.g., empagliflozin or dapagliflozin) unless contraindicated or intolerant (prerequisite Part D drug required).

    • For HF with LVEF ≥40%: document trial of an SGLT2 inhibitor or a contraindication/intolerance
    Note
    Note
    Documentation Required

    Liraglutide — PA: T2DM documentation required; excluded for weight‑loss only; 1 year

    Liraglutide (INJ 6 mg/mL) requires prior authorization and is excluded if used solely for weight loss. For ongoing treatment of type 2 diabetes, submit medical records/chart notes confirming T2DM or lab evidence (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hour OGTT ≥200 mg/dL); coverage duration is one year.

    • Excluded if used for weight‑loss only
    • For T2DM: submit chart notes OR labs (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL)
    • Coverage duration: 1 year
    Note

    General PA duration/prerequisites — 1 year common; check product PA for trials

    General PA durations and prerequisite patterns: many products list a one‑year coverage duration and some require prior trials of specified Part D therapies before approval; refer to each product's PA criteria for details.

    Step Therapy

    Step therapy — general; Acitretin exempt from prerequisite Part D drug

    Some formulary drugs are subject to step therapy and may require prior treatment with one or more formulary drugs before coverage; the Acitretin entry explicitly states it does not require a prerequisite Part D drug.

    • Acitretin: no prerequisite Part D drug required
    Step Therapy

    Briviact — step/prerequisite: trial of levetiracetam + one other agent

    Briviact requires a trial of levetiracetam and one other antiseizure medication prior to coverage per the product PA entry (prerequisite Part D drug required).

    Step Therapy

    Step therapy/prerequisite trials — providers must document required prior trials

    Many products require prerequisite therapy trials (examples in the PA list include trials of second‑generation antipsychotics, sorafenib for HCC, generic topical trials for calcipotriene, and prior systemic therapy lines for oncology agents); providers must document these prior trials as specified.

    Step Therapy

    Diacomit — prerequisite trial + combination requirement

    Diacomit requires trial of two generic anticonvulsants and combination use with clobazam prior to coverage; absence of documented trials may lead to denial.

    • Trial of 2 generic anticonvulsants
    • Combination with clobazam required
    Step Therapy

    Dihydroergotamine — prerequisite triptan trials required

    Dihydroergotamine mesylate solution requires trial of two triptans (one oral and one non‑oral) on the formulary prior to approval; providers must document these trials.

    • Trial one oral triptan and one non‑oral triptan required
    Step Therapy

    Dupixent — prerequisite therapy trials vary by indication; document trials and diagnostics

    Dupixent's indication‑specific PA entries require documented trials of specific prior therapies (e.g., high‑potency topical corticosteroid or listed systemic agents for atopic dermatitis; systemic corticosteroids and additional controller meds for eosinophilic asthma); providers must document prior trials and diagnostic criteria.

    Step Therapy

    Ebglyss — prerequisite therapy and documentation for AD in ≥12 years

    Ebglyss requires prior trials of listed topical or systemic agents for atopic dermatitis coverage in patients ≥12 years; providers must document prior trial failure and patient weight (≥40 kg).

    • Document trial and failure of listed topical/systemic agents for AD
    • Document patient weight ≥40 kg
    Note

    Provider help desk — contact for PA/ST requests

    Providers can contact the pharmacy help desk listed on the member ID card to request prior authorization or step therapy; use the customer service number for questions about drug coverage or claims.

    Documentation Required

    Bronchitol — required medical information: tolerance test

    Bronchitol coverage requires documentation that the member has passed the Bronchitol tolerance test; include that documentation with the PA request.

    • Submit Bronchitol tolerance test documentation
    Documentation Required

    General documentation — document prior trials and required medical information

    General documentation note: product PA entries list required prior trials, required medical information, and other criteria; providers should document prior use of required medications, diagnostics, and response information where specified to avoid denial.

    Documentation Required

    Cosentyx — reauthorization requires positive clinical response documentation

    Cosentyx reauthorization requires documentation of a positive clinical response to therapy; include objective evidence of improvement when submitting continuation requests.

    Documentation Required

    Dupixent — reauthorization requires clinical response documentation

    Reauthorization for Dupixent requires documentation of positive clinical response to therapy; ensure continuation requests include measures of clinical improvement per the indication.

    Documentation Required

    Ebglyss — reauth requires clinical response; prior trial documentation for AD

    Ebglyss reauthorization requires documentation of positive clinical response; for AD in patients ≥12 years, providers must document prior trials of listed therapies and treatment failure.

    Documentation Required

    Weight requirement — document patient weight where required (e.g., ≥40 kg)

    Weight requirement: several products (e.g., Ebglyss) require patient weight documentation; for Ebglyss the patient must weigh at least 40 kilograms.

    • Document patient weight (≥40 kg for Ebglyss)
    Documentation Required

    Reauthorization — document positive clinical response for biologics

    Reauthorization for biologics such as Enbrel and Kevzara requires documentation of a positive clinical response to therapy; include objective evidence of improvement when requesting continuation.

    Documentation Required

    Fasenra — document eosinophil/EGPA criteria and clinical response at reauth

    Fasenra reauthorization requires documentation of positive clinical response; initial PA also requires documentation of indication‑specific criteria such as eosinophil counts or EGPA features.

    Documentation Required

    Eucrisa — prerequisite documentation: generic topical steroid trial

    Eucrisa coverage for atopic dermatitis requires documentation of a trial of a generic topical steroid prior to approval; providers must include evidence of that trial.

    • Document trial of a generic topical steroid
    Denial Risk

    Forteo — BMD and prior trial documentation required; denial risk if missing

    Forteo coverage requires BMD documentation with a T‑score ≤ −2.5 and documentation of prior trials of the specified agents (or inability to tolerate them); failure to provide prerequisite trial documentation may trigger denial.

    Step Therapy

    Isotretinoin — step requirement: trial of antibiotic or benzoyl peroxide topical

    Isotretinoin coverage requires a documented trial of either an oral antibiotic or a benzoyl peroxide topical prior to approval; include that trial documentation with the PA request.

    • Document trial of oral antibiotic OR benzoyl peroxide topical
    Step Therapy

    Inqovi — prerequisite: trial with azacitidine required

    Inqovi coverage requires a documented trial with azacitidine prior to approval; failure to document this prerequisite may lead to denial.

    Step Therapy

    Livtencity — prerequisite antiviral trial required for post‑transplant CMV

    Livtencity coverage for post‑transplant CMV infection/disease requires a trial of valganciclovir, cidofovir, or foscarnet prior to approval; document the antiviral trial to support PA.

    • Document trial of valganciclovir, cidofovir, or foscarnet
    Step Therapy

    Lonsurf — prerequisite chemo + anti‑VEGF and bevacizumab combination required

    Lonsurf coverage for metastatic colorectal cancer requires prior combination use with bevacizumab and trials of fluoropyrimidine‑, oxaliplatin‑, irinotecan‑based chemotherapy and an anti‑VEGF; document prior chemotherapy and targeted therapy as specified.

    Step Therapy

    Lumakras — prerequisite: at least one prior systemic therapy for KRAS G12C NSCLC

    Lumakras coverage for KRAS G12C‑mutated NSCLC requires documentation of at least one prior systemic therapy; include prior systemic therapy history with the PA request.

    Denial Risk

    Combination biologic/targeted DMARD exclusion — may trigger denial

    Combination biologic/targeted DMARD exclusion: multiple product entries (e.g., Cosentyx, Dupixent, Enbrel, Kevzara, Humira, Fasenra) explicitly prohibit use in combination with another biologic or targeted DMARD for the same condition; use of combination therapy may trigger denial.

    • Do not use with another biologic/targeted DMARD indicated for the same condition — may trigger denial
    Denial Risk

    Tadalafil — exclusion with concurrent nitrate therapy

    Tadalafil is explicitly excluded when patients are receiving nitrate therapy; coverage will not be provided in that situation.

    Denial Risk

    Dalfampridine — exclusion if patient is wheelchair‑bound

    Dalfampridine is excluded for use if the patient is wheelchair‑bound or becomes wheelchair‑bound; do not authorize treatment for wheelchair‑bound patients.

    Documentation Required

    General documentation note — submit required tests, labs, and prior trial records

    Providers must document required medical information and prior trials as specified in each product's PA criteria (examples: Bronchitol tolerance test, baseline T25FW for dalfampridine, BMD for Forteo, lab evidence for GLP‑1 agonists) to support authorization requests and avoid denial.

    • Bronchitol tolerance test documentation (Bronchitol)
    • Baseline T25FW (Dalfampridine)
    • BMD T‑score documentation (Forteo)
    • A1c/FPG/OGTT labs or T2DM chart notes (GLP‑1 agonists)
    Denial Risk

    Prerequisite trial/documentation missing — denial risk

    Failure to provide documentation of prerequisite trials, diagnostic thresholds, or required tests (e.g., prior therapy trials for oncology agents, antiviral trials for Livtencity, azacitidine for Inqovi) may result in denial of coverage; verify and include all required information on the PA request.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Acceptable evidence when submitting GLP‑1 agonist PA for ongoing treatment of type 2 diabetes mellitus
    DocumentationSubmission of medical records/chart notes confirming diagnosis of T2DM or lab evidence required
    Fasting plasma glucose threshold for diabetes documentation
    Fasting plasma glucose (FPG) threshold>= 126 mg/dL
    Use contextAcceptable laboratory evidence for T2DM when requesting GLP‑1 agonist prior authorization
    DocumentationSubmit medical records/chart notes or lab report showing FPG meeting threshold
    2-hour plasma glucose (OGTT) threshold for diabetes documentation
    2‑hour plasma glucose (OGTT) threshold>= 200 mg/dL during OGTT
    Use contextAcceptable laboratory evidence for T2DM when requesting GLP‑1 agonist prior authorization
    DocumentationProvide OGTT result in medical records/chart notes to support PA request
    ExamplesST examples include trials of generic anticonvulsants, trials of specific DMARDs or NSAIDs, or combination therapy prerequisites for oncology agents
    All Medically-accepted Indications — explanation
    Meaning'All Medically‑accepted Indications' indicates the product is covered for recognized clinical uses subject to the listed PA criteria
    ImplicationCoverage for such indications still requires submission of required medical information and meeting any prerequisite therapy or exclusion rules
    DocumentationProviders should refer to the product PA entry for specific required information and criteria details
    Exclusion Criteria — combination biologic exclusion definition
    DefinitionExclusion: combination biologic — use in combination with another biologic or targeted DMARD indicated for the same condition is not permitted
    ConsequencesSuch combination use is listed as an exclusion and may trigger denial of coverage
    ExamplesExplicitly stated for multiple products (e.g., Ebglyss, Kevzara, Humira entries)
    Prerequisite Therapy — definition of required prior trials
    DefinitionPrerequisite therapy — a required prior trial of specific Part D drugs or drug classes (e.g., DMARDs, NSAIDs) before coverage is authorized
    PurposeEnsures prior, less costly or standard therapies were tried and failed or were intolerable before approving advanced therapies
    ExamplesRA: trial of a DMARD; AS: trial of one NSAID; Kevzara for RA: trial of two listed agents
    PA Criteria — reference to where full criteria details are located
    Where to find full criteriaEach product line references 'PA Criteria = Criteria Details' where full, product‑specific authorization criteria are located
    Typical contentFull PA criteria include indication specifics, required documentation, exclusions, age/prescriber limits, coverage duration, and prerequisite therapy
    Action for providersRefer to the detailed PA Criteria section for complete logic and submission requirements when preparing an authorization request
    Positive clinical response — documentation required for reauthorization
    DefinitionPositive clinical response — documentation of clinical improvement while on therapy required for reauthorization
    Use in reauthorizationReauthorization for many biologics (e.g., Cosentyx, Enbrel, Fasenra, Humira, Kevzara) requires evidence of positive clinical response
    Documentation examplesProgress notes, objective measures (e.g., reduced symptom scores, improved lab/imaging results) or clinician assessment documenting improvement

    Document notes 'Effective Date: 07/01/2026' and 'Last Updated: 07/01/2026' confirming publication details for this plan year.